Now showing items 1-6 of 6
Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome
(Wiley Periodicals, Inc., 2020-04-17)
Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). Methods: Plasma samples were ...
Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study
(Wiley Periodicals, Inc., 2020-06-30)
Introduction: Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) ...
Accelerating Hyperparameter Tuning in Machine Learning for Alzheimer's Disease With High Performance Computing
(Frontiers Media S.A., 2021-12-08)
Driven by massive datasets that comprise biomarkers from both blood and magnetic resonance imaging (MRI), the need for advanced learning algorithms and accelerator architectures, such as GPUs and FPGAs has increased. Machine ...
The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics
(Wiley Periodicals, LLC, 2021-06-21)
Introduction: Mexican Americans remain severely underrepresented in Alzheimer's disease (AD) research. The Health & Aging Brain among Latino Elders (HABLE) study was created to fill important gaps in the existing literature. ...
Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study
(Wiley Periodicals, LLC, 2022-02-09)
Introduction: We sought to examine a magnetic resonance imaging (MRI)-based marker of neurodegeneration from the AT(N) (amyloid/tau/neurodegeneration) framework among a multi-ethnic, community-dwelling cohort. Methods: ...
A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials
(IOS Press, 2021-05-18)
Background: The REFLECT trials were conducted to examine the treatment of mild-to-moderate Alzheimer's disease utilizing a peroxisome proliferator-activated receptor gamma agonist. Objective: To generate a predictive ...